Arcserve Introduces Multi-Petabyte Appliances for the Market’s Only Means to Secure Big Data from Cyberattacks, IT Disasters and Large-Volume Data Loss

New X Series Appliances combine advanced backup, cybersecurity and disaster recovery (DR) capabilities with over 3PBs of effective capacity to solve for unstoppable data growth, unabated cyber threats and IT disasters

MINNEAPOLIS, Dec. 08, 2020 (GLOBE NEWSWIRE) — Arcserve, LLC, the world’s most experienced data and ransomware protection provider, today unveiled Arcserve X Series Appliances Secured by Sophos, the first self-contained solutions with integrated cyber and data protection for enterprise data volumes. The new appliances uniquely combine deep learning endpoint protection and on- and off-site disaster recovery with over 3PBs of effective capacity in one unit, and linear expansion to increase capacity as needed.

According to the recently released Sophos 2021 Threat Report, organizations are hard-pressed to predict the evolution of cyber threats because ransomware gangs are constantly devising new tactics to hold critical data hostage and solicit ransom payments. For that reason, enterprises must take a proactive approach through an integrated first and last line of defense that offers ransomware prevention, detection and removal, and if needed, automated restore to on-site and cloud targets.

“Most practitioners in the IT community understand the extreme wreckage ransomware often leaves in its wake,” said Phil Goodwin, Research Director, IDC. “Integrating cybersecurity and data protection as a coordinated deployment is critical, of which Arcserve has staked its position at the forefront of this market. The new X Series Appliances expand these integrated technologies and are designed to create a robust system scalable for enterprise data centers.”  

Data protection and security at scale

Arcserve X Series Appliances uncomplicate enterprise infrastructures and offer a higher ROI by eliminating discrete data protection and security strategies:

  • Powered by Arcserve UDP software, organizations protect complex workloads with heterogeneous technologies that can be unboxed and deployed in under 15 minutes;  
  • Integrate Sophos Intercept X Advanced cybersecurity to prevent ransomware and hacker attacks, including credential harvesting, lateral movement and privilege escalation;
  • Protect entire enterprise data centers with over 3PBs of effective capacity per unit; and,
  • Increase capacity as needed with linear expansion.

Performance-driven architecture

To stay ahead of new and existing challenges, IT organizations require solutions with extreme performance and agility:

  • Architected with cloud-native technologies, the X Series enables cloud economies of scale by combining on- and off-site backup and rapid restore to public and private clouds, including Arcserve® Cloud, Amazon® AWS, Microsoft Azure®, Nutanix® Objects, Eucalyptus®, Rackspace®, and more;
  • Instant VM and BMR, local and remote virtual standby, application-consistent backup and granular restore, optional high availability, and more;
  • 56 CPU cores and 1TB RAM (expandable to 2TBs) to spin up dozens of VMs on-appliance; and,
  • Hyper-efficient global deduplication with enterprise-grade SAS HDDs and NVMe SSDs for up to 20:1 ratios.

“As the threat landscape evolves and data becomes more distributed in our work-from-home reality, it’s become more critical than ever to invest in the highest-performing tools and services to keep priceless data safe,” said Ivan Pittaluga, CTO of Arcserve. “And, as more data is being produced it’s equally important that organizations have a solution that can grow with them. Our new appliances are changing the game –giving organizations with enterprise-level data volumes the opportunity to use one solution for backup, cybersecurity, on-appliance and cloud disaster recovery with options for high availability. No other appliance can do that, which is why we’re so pleased to offer differentiated value that not only offers significantly higher ROI, but peace of mind.”

Learn more about Arcserve X Series Appliances Secured by Sophos.

Follow Arcserve

About Arcserve

Arcserve provides exceptional solutions to protect the priceless digital assets of organizations in need of full scale, comprehensive data protection. Established in 1983, Arcserve is the world’s most experienced provider of business continuity solutions that safeguard multi-generational IT infrastructures with applications and systems in any location, on premises and in the cloud. Organizations in over 150 countries around the world rely on Arcserve’s highly efficient, integrated technologies and expertise to eliminate the risk of data loss and extended downtime while reducing the cost and complexity of backing up and restoring data by up to 50 percent. Arcserve is headquartered in Minneapolis, Minnesota with locations around the world. Explore more at www.arcserve.com and follow @Arcserve on Twitter.

Contacts

Leslie Keil
Arcserve
952.903.5434
[email protected]

Jackie Blundell
Red Lorry Yellow Lorry
857.217.2886
[email protected]



Hallgarten & Company Initiates Coverage of Ceylon Graphite

VANCOUVER, British Columbia, Dec. 08, 2020 (GLOBE NEWSWIRE) — Ceylon Graphite Corp. (“Ceylon Graphite”or the “Company”) (TSX-V: CYL) (OTC: CYLYF) (FSE: CCY) is pleased to announce that Christopher Ecclestone of Hallgarten & Company has initiated coverage of Ceylon Graphite. A copy of the research report is available at https://www.hallgartenco.com/pdf/Battery/Ceylon%20Graphite_Dec2020.pdf.

The company would also like to remind interested parties that management will be hosting an investor webinar today, December 8, 2020 at 12:00 PM EST to provide participants an overview of the Company, its exciting recent developments and how the Company is positioned to be a significant participant in the high-growth electric vehicle and battery storage markets.

An updated investor presentation has also been posted on the Company’s website www.ceylongraphite.com

When: Tuesday, December 8, 2020 at 12:00 PM EST
Registration link:https://my.6ix.com/DveBYPHa

R
esearch R
e
port
H
ighlights

  • Production is up and running at Ceylon Graphite’s subsidiary Sarcon Development (Pvt) Ltd.’s K1 mine, putting it amongst the select group of active graphite producers.
  • Compared to other graphite mines the Company’s K1 and M1 mines have been inexpensive to develop, with some of the lowest production cost globally.
  • Sri Lankan natural graphite sells at US$2,000 to US$2,300 per ton, a significant premium to all grades of flake graphite. High grades (95% Cg plus) provide significant margins and make the product suitable for upgrading to battery grade, high value products.
  • Samples from both K1 and M1 have been tested by Dorfner ANZAPLAN and American Energy Technologies and certified upgradeable to battery 99.99% purity.
  • The Company has a large land package of over 121 grids with significant evidence of past production.
  • Ceylon Graphite recently raised $4,500,000 through equity financing in October 2020 and is well capitalized with no debt.

Bharat Parashar, Chief Executive Officer of Ceylon Graphite said: “Christopher is a well-known and respected analyst in the Graphite space and we are pleased that he has initiated coverage with a very positive outlook for our company as well as industry macro factors.”

Positive
Graphite Industry M
acro
D
evelopments

  • Graphite demand is widespread – steel foundries and refractories, lubricants, automotive, batteries/energy storage and military applications.
  • Chinese production cutbacks and limitations on needle-coke supply (for synthetic Graphite) have underpinned prices.
  • China is now increasingly importing high quality Graphite to meet domestic demand.
  • The Electric Vehicle (EV) revolution continues to accelerate with graphite serving as the key component in the Lithium-ion battery.
  • There is market sentiment that major Western end-users want to diversify graphite supply to reduce reliance on Chinese production. The United States government has recently declared graphite a critical mineral to its interests.
  • The underpinnings for an optimistic outlook on graphite prices include:
         • Production and supply problems in China due to stricter enforcement of environmental and safety standards and restrictions on extraction techniques.
          • Steel industry recovery.
          • Continued strong growth in Lithium ion battery demand.
          • XL flake production decline as resources in Shandong Province, a major source, are being depleted.


About Ceylon Graphite Corp.

Ceylon Graphite is a public company listed on the TSX Venture Exchange, that is in the business of mining for graphite, plus the exploration for and development of graphite mines in Sri Lanka. Graphite mined in Sri Lanka is known to be some of the purest in the world and has been confirmed to be suitable to be easily upgradable for a range of applications including the high-growth electric vehicle and battery storage markets. The Government of Sri Lanka has granted the Company’s wholly own subsidiary Sarcon Development (Pvt) Ltd. an IML Category A license for its K1 site and exploration rights in a land package of over 120km². These exploration grids (each one square kilometer in area) cover areas of historic graphite production from the early twentieth century and represent a majority of the known graphite occurrences in Sri Lanka.

Hallgarten & Company has acted as a strategic consultant to Ceylon Graphite and has been compensated for those services in the past, but it does not hold any stock in the company, nor does it have the right to hold any stock in the future.

Further information regarding the Company is available at www.ceylongraphite.com

Bharat Parashar, Chairman and & Chief Executive Officer
[email protected]
Corporate Communications
+1(202)352-6022

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release

FORWARD LOOKING STATEMENTS:

This news release contains forward-looking information as such term is defined in applicable securities laws, which relate to future events or future performance and reflect management’s current expectations and assumptions. The forward-looking information includes statements about Ceylon Graphite’s grids, Ceylon Graphite’s plans to undertake additional drilling and to develop a mine plan, and to commence establishing mining operations. Such forward-looking statements reflect management’s current beliefs and are based on assumptions made by and information currently available to Ceylon Graphite, including the assumption that, there will be no material adverse change in metal prices, all necessary consents, licenses, permits and approvals will be obtained, including various Local Government Licenses and the market. Investors are cautioned that these forward-looking statements are neither promises nor guarantees and are subject to risks and uncertainties that may cause future results to differ materially from those expected. Risk factors that could cause actual results to differ materially from the results expressed or implied by the forward-looking information include, among other things, an inability to reach a final acquisition agreement, inaccurate results from the drilling exercises, a failure to obtain or delays in obtaining the required regulatory licenses, permits, approvals and consents, an inability to access financing as needed, a general economic downturn, a volatile stock price, labour strikes, political unrest, changes in the mining regulatory regime governing Ceylon Graphite, a failure to comply with environmental regulations and a weakening of market and industry reliance on high quality graphite. Ceylon Graphite cautions the reader that the above list of risk factors is not exhaustive.

These forward-looking statements are made as of the date hereof and, except as required under applicable securities legislation, Ceylon Graphite does not assume any obligation to update or revise them to reflect new events or circumstances. All of the forward-looking statements made in this press release are qualified by these cautionary statements and by those made in our filings with SEDAR in Canada (available at www.sedar.com)

 



Well+Good Launches Annual Wellness Trends Report

Highly Anticipated Annual Report Includes a State of the Union in Wellness and Predicts What’s Ahead in the Health & Wellness Industry in 2021

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) — Well+Good, a leading health and wellness media brand known for its journalistic approach and commitment to creating inclusive content accessible to all, announced today the launch of its 11th annual Wellness Trends report. The report examines the massive shifts that have shaken up every aspect of the wellness industry this year—how we work out, what we eat, the products we put on our faces, the way we rest—and how the reverberations of those changes will be felt into 2021 and beyond.

This year’s Wellness Trends report takes an investigative deep dive into six wellness categories that have been most affected by the changes of 2020: Beauty, Fitness, Food, Self Care, Health, and Home, and spotlights the movements, micro-trends, and products that will gain traction in 2021. 

“The wellness landscape has undergone a complete transformation since the first annual Well+Good Wellness Trends report in 2009, and as we navigate the systemic shifts of this year, it is clear that how we all think about our health and well-being has fundamentally changed,” said Kate Spies, General Manager of Well+Good. “In 2021, we expect to see many positive, structural changes across all verticals, and our hope is that these necessary changes will lead to a more diverse, equitable, sustainable and factual future for the wellness industry as a whole.”

Highlights from the report include:

  • High-Tech Sneakers Will Give Runners a Performance Boost: in 2021, shoe technology that was once reserved for making the world’s top athletes perform harder, better, faster, stronger will be available to consumers. Look out for carbon fiber plates in the shoe’s footbed, which help to propel runners forward, making every step more energy-efficient. Another high-tech feature that will become more available to the public in 2021 is lightweight, energy-transferring foam that helps with speed and cushion, which protects the runner’s joints.
  • Pandemic Personal Care is a New Category of Beauty Products: an unexpected side effect of increased hand-washing, face masks, and days spent entirely indoors are the rise of a whole new category of beauty products aimed at solving the resulting new skin-care woes. Beauty brands are launching elevated, skin-friendly soaps, sanitizers, and creams, and in 2021, expect even more products for your hands formulated with the ingredients usually reserved for your face, such as a hand “serum,” hand cream infused with avocado oil and hyaluronic acid, and vitamin E-rich balms gentle enough to be used on hands, body, and face.
  • Adaptogenic
    Mushrooms Will Enjoy Even More Function in 2021: mushroom varieties that benefit cognitive health, stress levels, and immune support have been a staple in East Asian medicinal traditions for decades, and in 2021 the potential of mushrooms for supporting health is moving into the mainstream American market. Product innovation has improved the taste of these functional mushrooms, so expect to see them incorporated into lattes, salad dressings, and even chewing gum.
  • Upcycled Food Products Are Coming
    To
    Shrink Your Food Waste: next year, look for brands producing a slate of new products that repurpose bits of food that would otherwise go to waste into new items. Examples include “imperfect” bananas turned into snacks, surplus fruits and vegetables turned into protein powders, and salmon chips made from salmon skin.
  • A New Generation of Youth Wellness Programs Is Growing Up: the pandemic has brought a new urgency to the creation of wellness programs geared towards kids and teens. Pair that with a growing awareness among younger generations of self care and mindfulness practices as a way to cope with mounting stressors, and wellness is poised for an injection of teen spirit in 2021.
  • Tracking Stress is the New Tracking Steps: in 2021, a growing number of wearables will be tracking stress and helping wearers do something about it. These devices will give wearers a stress “score” and specific stress management tips tailored to lower that score over time. Next year, stress tracking will fit right alongside markers of a healthy lifestyle like exercise, nutrition and sleep.

To view the full Wellness Trends report, visit https://www.wellandgood.com/fitness-wellness-trends/. Join Well+Good for the brand’s first-ever virtual Wellness Trends event on December 8. To register for this free event, visit https://wg-wellnesstrends2021.splashthat.com/

About
Well+Good


Well+Good is a leading health and wellness media brand known for its journalistic approach to content and ahead-of-the-curve trend-spotting. Well+Good is committed to creating inclusive content that makes health and wellness accessible to all and aims to amplify different perspectives, experiences, and stories. The female-founded company, bootstrapped since its debut in 2010, has been recognized as a vertical media leader and was named to Fast Company’s 2018 Most Innovative Companies list. The brand also creates high-quality consumer events, including its Well+Good Talks and Well+Good Retreats series. For more information, visit www.wellandgood.com.

About Leaf Group:

Leaf Group Ltd. (NYSE: LEAF) is a diversified consumer internet company that builds enduring, creator-driven brands that reach passionate audiences in large and growing lifestyle categories, including fitness and wellness (Well+Good, Livestrong.com and MyPlate App), and home, art and design (Saatchi Art, Society6 and Hunker). For more information about Leaf Group, visit www.leafgroup.com.

Media Contacts

Susan Turner
Director of PR, Fitness & Wellness
[email protected]

Sharna Daduk
Vice President, Communications
[email protected]



Altimmune Commences Dosing in Phase 1 Clinical Trial of ALT-801, a Long-Acting GLP-1/Glucagon Receptor Dual Agonist for the Treatment of NASH

Preclinical data suggest potential for ALT-801 to address a significant unmet medical need; Phase 1 data readout anticipated in Q2 2021

GAITHERSBURG, Md., Dec. 08, 2020 (GLOBE NEWSWIRE) — Altimmune, Inc. (Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has commenced dosing in a Phase 1 single ascending dose (SAD) and multiple ascending dose (MAD) clinical study of ALT-801. ALT-801 is a long-acting GLP-1/glucagon receptor dual agonist being developed for the treatment of non-alcoholic steatohepatitis (NASH), which is expected to affect more than 13 million adults in the United States.

The Phase 1 clinical trial is being conducted in Australia and is expected to enroll approximately 50 and 60 volunteers in the SAD and MAD phases of the trial, respectively. The trial is designed to evaluate the safety, pharmacokinetics and activity of ALT-801 over 6 weeks of treatment in overweight and obese but otherwise normal volunteers. Readouts from the trial, including initial weight loss and liver fat reduction, are expected in the second quarter of 2021. This 6-week study will be followed by a 12-week Phase 1b study in volunteers with non-alcoholic fatty liver disease (NAFLD) and is expected to commence in the third quarter of 2021.

“There is significant need for an effective, well-tolerated treatment for NASH,” said Scott Harris, M.D., Chief Medical Officer of Altimmune. “Unlike other metabolic approaches to treat NASH, ALT-801 combines the balanced, equipotent effects of GLP-1 and glucagon activities into a single peptide. The approach is expected to provide optimal effects in activating both a satiety signal to reduce appetite while also stimulating energy expenditure to promote a reduction in liver fat and increased weight loss. The Company anticipates that ALT-801, administered once-weekly, will have a favorable pharmacokinetic profile and improved gastrointestinal (GI) tolerability due to the proprietary EuPort™ domain, which slows the entry of the drug into the circulation. As GI intolerability is a significant limiting factor with all current GLP-1 based treatments, an improved tolerability profile is expected to be regarded favorably among clinicians. We look forward to a readout from the study in the second quarter of 2021, which could support strong competitive positioning for ALT-801 in the NASH treatment landscape.”

About ALT-
801

ALT-801 is a novel peptide-based dual GLP-1/glucagon receptor agonist that is designed to treat the obesity and metabolic dysfunction that causes NASH. As the most severe form of non-alcoholic fatty liver disease, or NAFLD, NASH involves multiple metabolic pathways leading to the abnormal accumulation of liver fat, toxic lipid metabolites, and inflammation, resulting ultimately in fibrosis (cirrhosis) or liver cancer. Altimmune believes the treatment of obesity is the cornerstone of treating NASH and the principal morbidities of NASH. As observed in a well-established preclinical model of the disease, ALT-801 was capable of inducing significantly greater weight loss compared to semaglutide, a GLP-1 receptor agonist, along with significantly greater decreases in liver fat, plasma ALT, and other markers of NASH.

About Altimmune

Altimmune is a clinical stage biopharmaceutical company focused on developing intranasal vaccines, immune modulating therapies and treatments for liver disease. Our diverse pipeline includes proprietary intranasal vaccines for COVID-19 (AdCOVID™), anthrax (NasoShield™) and influenza (NasoVAX™); an intranasal immune modulating therapeutic for COVID-19 (T-COVID™); and next generation peptide therapeutics for NASH (ALT-801) and chronic hepatitis B (HepTcell™). For more information on Altimmune, please visit www.altimmune.com.

Forward-Looking Statement

Any statements made in this press release relating to future financial or business performance, conditions, plans, prospects, trends, or strategies and other financial and business matters, including without limitation, the safety, efficacy and clinical progress of ALT-801 (including, without limitation, the expected timing of the Phase 1 clinical trial results) and the prospects for regulatory approval, commercializing or selling any product or drug candidates, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. In addition, when or if used in this press release, the words “may,” “could,” “should,” “anticipate,” “believe,” “estimate,” “expect,” “intend,” “plan,” “predict” and similar expressions and their variants, as they relate to Altimmune, Inc. (the “Company”) may identify forward-looking statements. The Company cautions that these forward-looking statements are subject to numerous assumptions, risks, and uncertainties, which change over time. Important factors that may cause actual results to differ materially from the results discussed in the forward looking statements or historical experience include risks and uncertainties, including risks relating to: potential impacts due to the COVID-19 pandemic such as delays in regulatory review, manufacturing and supply chain interruptions, access to clinical sites, enrollment, adverse effects on healthcare systems and disruption of the global economy the reliability of the results of studies relating to human safety and possible adverse effects resulting from the administration of the Company’s product candidates; the Company’s ability to secure regulatory approval for its AdCOVID investigational new drug application submission to the U.S. Food and Drug Administration, the Company’s ability to manufacture clinical trial materials on the timelines anticipated; the Company’s ability to secure manufacturing approval from its SARS-CoV-2 cell licensor on the timelines anticipated; and the success of future product advancements, including the success of future clinical trials. Further information on the factors and risks that could affect the Company’s business, financial conditions and results of operations are contained in the Company’s filings with the U.S. Securities and Exchange Commission, including under the heading “Risk Factors” in the Company’s annual report on Form 10-K for the fiscal year ended December 31, 2019 and quarterly report on Form 10-Q for the quarter ended March 31, 2020 filed with the SEC, which are available at www.sec.gov.

Investor Contacts:  
   
Will Brown Ashley R. Robinson
Chief Financial Officer LifeSci Advisors, LLC
Phone: 240-654-1450 617-430-7577
[email protected] [email protected]
   
Stacey Jurchison  
Sr. Director, Investor Relations  
Phone: 410-474-8200  
[email protected]  



Ubersmith Brings Together 50 Disparate Business Operations Systems at Atlantic.Net

Greatly improves efficiency, more precise billing, better overall customer service

NEW YORK, Dec. 08, 2020 (GLOBE NEWSWIRE) — Atlantic.Net Inc., a global cloud services provider, replaced or integrated more than 50 different subscription billing, device management and customer support systems into one. Ubersmith business management software has improved business processes from seven to 14 days to one day, quickened response to support issues by enabling resolution in half of the previous time and realized a 55% improvement in billing for customers’ overage usage.

“By consolidating all our previous systems into Ubersmith, customer information related to billing, products and service is centralized in one place, making it readily accessible,” said Marty Puranik, founder and CEO, Atlantic.Net. “Plus, we’ve eliminated the need for training our staff on different systems, which saves countless hours and streamlines resources.”

“We can automatically tie support tickets to information about specific devices and customers, and as a result, our support ticket times have dropped in half,” said Puranik. “Also, we have better capabilities to monitor customer usage and bill accordingly, which is a net positive for revenue growth.”

Atlantic.Net has achieved tremendous operational efficiencies and substantial cost savings by eliminating many redundant systems.

Started in 1994 in Gainesville, Florida, Atlantic.Net quickly expanded to other cities with new office openings and acquisitions of service providers. Today, it operates out of five data centers in the U.S., one in Canada, and one in the U.K., with plans to expand services in Amsterdam and Singapore next year. Atlantic.Net is a global cloud services provider, providing more than 15,000 customers with business-class dedicated and cloud hosting solutions backed by 24/7/365 support.

Ubersmith is an easily customizable, integrated, and modular software suite for subscription billing, quoting, order management, infrastructure management and ticketing. A plug-in system provides flexibility for extending and integrating other software used as part of business operations. Ubersmith provides an application programming interface (API) and software development kit (SDK) to enable customers and partners to easily integrate other systems and programs with the Ubersmith suite.

“We make extensive use of Ubersmith APIs to integrate with other systems that we use for payments, accounting, domain registration, security certificates and more,” said Puranik.

Deep integrations with the Ubersmith software enable Atlantic.Net to achieve high levels of efficiency in operations, helping to improve employee productivity and ultimately provide higher levels of customer service. Atlantic.Net is known for delivering outstanding products, service and high customer satisfaction with one of the lower customer churn rates in the VPS hosting industry.

With Ubersmith’s plans to soon add support for Salesforce, Atlantic.Net will be able to tie in its sales and prospecting activities, along with customer quotes, in its systems.

“Atlantic.Net has done an impressive job at leveraging the capabilities we provide in Ubersmith’s business management, infrastructure and operations software,” said Kurt Daniel, CEO of Ubersmith. “We’re pleased to be an important partner for their business as they continue to grow and expand in the cloud services and hosting arenas.”

About Atlantic.Net

Atlantic.Net is a global cloud services provider with over 25 years of experience, specializing in managed and non-managed Windows, Linux, and FreeBSD server hosting solutions and HIPAA compliant hosting. With a focus on security, compliance, and simplifying the user experience, Atlantic.Net provides business-class dedicated and cloud hosting solutions, backed by 24/7/365 support through their global data centers located in New York, London, San Francisco, Toronto, Dallas, Ashburn, and Orlando. For more information, please visit https://www.atlantic.net.

About Ubersmith

Ubersmith is a leader in subscription management software for the cloud and beyond. Headquartered in New York, Ubersmith provides billing, infrastructure and ticketing solutions that are open, scalable, and integrated. Organizations worldwide rely on Ubersmith to better serve their customers and better run their businesses. For more, please visit https://ubersmith.com.



Glenn Rossman
(914) 623-8354
[email protected]

Panbela Therapeutics, Inc. Completes Enrollment in its Phase 1b Trial Investigating SBP-101 Combination Therapy for First Line Metastatic Pancreatic Cancer

· Phase 1b Data Expected 1H 2021

MINNEAPOLIS, Dec. 08, 2020 (GLOBE NEWSWIRE) —  Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, has completed patient enrollment in its Phase 1 trial evaluating the safety and tolerability of SBP-101 when used in combination with standard of care agents gemcitabine and nab-paclitaxel for first-line treatment of patients with metastatic pancreatic ductal adenocarcinoma (PDA). 

The trial, which included a dose escalation phase and an expansion phase, enrolled 50 patients, 30 of whom were treated using the dose and schedule that will advance to a randomized trial of the combination versus gemcitabine and nab-paclitaxel alone planned to begin in the first half of 2021.  In total, the safety of SBP-101 has been evaluated in 79 patients in two clinical trials.

“We are pleased to have completed enrollment in our Phase 1b trial and expect to announce data in the first half of next year,” commented Jennifer Simpson, PhD., M.S.N., C.R.N.P.  – President & Chief Executive Officer.  “Completing enrollment for SBP-101 marks an important milestone in our quest to bring new therapeutic options to patients with pancreatic cancer, which is an orphan disease and an area of unmet medical need.”

SBP-101 is currently being evaluated in a Phase 1a/1b clinical trial of patients with previously untreated metastatic PDA at sites in the United States and Australia. SBP -101 has received Fast Track and orphan drug designation from FDA.  For more information, please visit clinicaltrials.gov.

About SBP-101 

SBP-101 is a proprietary polyamine analogue designed to induce polyamine metabolic inhibition (PMI) by exploiting an observed high affinity of the compound for pancreatic ductal adenocarcinoma. The molecule has shown signals of tumor growth inhibition in clinical studies of US and Australian metastatic pancreatic cancer patients, suggesting complementary activity with an existing FDA-approved chemotherapy regimen. In clinical studies to date, SBP-101 has not shown exacerbation of the typical chemotherapy-related adverse events of bone marrow suppression and peripheral neuropathy. The safety data and PMI profile observed in the current Panbela sponsored current clinical trial provides support for continued evaluation of the compound in a randomized clinical trial.  For more information, please visit https://clinicaltrials.gov/ct2/show/NCT03412799.

About Panbela Therapeutics, Inc

Panbela Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing disruptive therapeutics for patients with urgent unmet medical needs. The company’s initial product candidate, SBP-101, is for the treatment of patients with metastatic pancreatic ductal adenocarcinoma, the most common type of pancreatic cancer. Panbela Therapeutics, Inc. is dedicated to treating patients with pancreatic cancer and exploring SBP-101’s potential for efficacy in combination with other agents and in treating other types of cancer. Further information can be found at: www.panbela.com. Panbela Therapeutics, Inc. common stock is listed on The Nasdaq Stock Market LLC under the symbol PBLA. 

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements,” including within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: “believes,” “ dedicated,” “expects,” “intends,” “may,” “milestone,” or “plans.” Examples of forward-looking statements include, among others, statements we make regarding, potential effects of FDA Fast Track designation, future determinations of the characteristics of SBP-101 and its effectiveness, uses of proceeds from recent financings. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations, and assumptions regarding the future of our business, future plans and strategies, projections, anticipated events and trends, the economy and other future conditions. Because forward-looking statements relate to the future, they are subject to inherent uncertainties, risks and changes in circumstances that are difficult to predict and many of which are outside of our control. Our actual results and financial condition may differ materially and adversely from the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important factors that could cause our actual results and financial condition to differ materially from those indicated in the forward-looking statements include, among others, the following: (i) our ability to obtain additional funding to complete a randomized clinical trial; (ii) progress and success of our Phase 1 clinical trial; (iii) the impact of the current COVID-19 pandemic on our ability to complete monitoring and reporting in our current clinical trial; (iv) our ability to demonstrate the safety and effectiveness of our SBP-101 product candidate (v) our ability to obtain regulatory approvals for our SBP-101 product candidate in the United States, the European Union or other international markets; (vi) the market acceptance and level of future sales of our SBP-101 product candidate; (vii) the cost and delays in product development that may result from changes in regulatory oversight applicable to our SBP-101 product candidate; (viii) the rate of progress in establishing reimbursement arrangements with third-party payors; (ix) the effect of competing technological and market developments; (x) the costs involved in filing and prosecuting patent applications and enforcing or defending patent claims; and (xi) such other factors as discussed in Part I, Item 1A under the caption “Risk Factors” in our most recent Annual Report on Form 10-K, any additional risks presented in our Quarterly Reports on Form 10-Q and our Current Reports on Form 8-K. Any forward-looking statement made by us in this press release is based on information currently available to us and speaks only as of the date on which it is made. We undertake no obligation to publicly update any forward-looking statement or reasons why actual results would differ from those anticipated in any such forward-looking statement, whether written or oral, whether as a result of new information, future developments or otherwise.



Contact Information:

Investors: 
James Carbonara 
Hayden IR 
(646) 755-7412 
[email protected]

Media: 
Tammy Groene 
Panbela Therapeutics, Inc. 
(952) 479-1196 
[email protected]

electroCore Announces Positive Top-Line Results from PREMIUM II Migraine Prevention Study

BASKING RIDGE, N.J., Dec. 08, 2020 (GLOBE NEWSWIRE) — electroCore, Inc. (Nasdaq: ECOR), a commercial-stage bioelectronic medicine company, announced today top-line results from its GM-US-10 (PREMIUM II) study. Despite the early termination of the study in April 2020 due to the COVID-19 pandemic, all study endpoints, including several patient-assessed quality of life measures, showed benefit from non-invasive vagus nerve stimulation (nVNS), with many endpoints showing a statistically significant improvement with nVNS compared to sham stimulation.

In the predefined modified intent to treat population (mITT; n=113), which was the designated primary analysis population for the study, patients using gammaCore™ nVNS had 3.1 less migraine days over the final four weeks of the 12 week double blind study period versus the four weeks of the run-in period as compared to a decrease of 2.3 migraine days in the sham group (primary endpoint; p=0.233).

Within the mITT population, 44.9% of the subjects using gammaCore™ nVNS had at least a 50% decrease in the number of migraine days compared to 26.8% for those receiving sham stimulation (secondary endpoint; p=0.048). Patients using gammaCore also reported a statistically significant decrease in migraine associated disability and improvement in their quality of life across all of the quality of life (QOL) endpoints in the study.

Of particular interest were the results in the predefined sub-population of patients diagnosed as having migraine with aura. In this group, patients using nVNS had 5.5 fewer headache days compared to 2.7 fewer headache days in the sham group (p=0.041). There were no serious adverse effects reported in the study, which is consistent with nVNS’ strong safety and tolerability profile.

Complete results of the study are expected to be published in early 2021 in a peer reviewed neurology journal. gammaCore™ received 510(k) clearance for the preventative treatment of migraine on March 26, 2020.

Dr. Umer Najib, MD, FAHS, Director of the West Virginia University Headache Center and an investigator in the PREMIUM II study, commented “I am pleased that nVNS continues to demonstrate its ability to effectively decrease the migraine burden in patients who need preventive therapy. The strong benefit seen in patients diagnosed with aura is particularly interesting as those patients can often be particularly difficult to treat.”

“The results of the PREMIUM II study highlight the unique role gammaCore nVNS can play as the only headache treatment that has demonstrated an ability to decrease the number of migraine days a patient experiences while also being able to treat the acute pain of migraines that occur in spite of a preventive regimen,” said Eric Liebler, SVP of Neurology at electroCore, Inc. “Although the ongoing COVID-19 pandemic negatively impacted our ability to fully enroll PREMIUM II, our analysis indicates we likely would have reached statistical significance on all of our predefined endpoints had the study reached its original enrollment targets. With FDA clearances for the acute and preventive treatment of both cluster and migraine headache, gammaCore continues to differentiate itself as one of the most effective, safe and flexible treatments available to help patients looking for a way to take control of their headache treatment.”

PREMIUM II was a randomized, double-blind, sham-controlled clinical trial of gammaCore™ for the prevention of migraine conducted at over 30 sites in the United States (ClinicalTrials.gov identifier NCT03716505). The study was originally designed based on mITT of approximately 300 subjects. The study was closed before reaching its original enrollment targets in Q2 of 2020 due to the impact of COVID-19 on the conduct of clinical trials, resulting in intent to treat (ITT) and mITT groups of 228 and 113, respectively.

About electroCore, Inc.
electroCore, Inc. is a commercial-stage bioelectronic medicine company dedicated to improving patient outcomes through its platform non-invasive vagus nerve stimulation therapy initially focused on the treatment of multiple conditions in neurology. The company’s current indications are the preventative treatment of cluster headache and migraine and acute treatment of migraine and episodic cluster headache.

For more information, visit www.electrocore.com.

About gammaCore
TM
gammaCoreTM (nVNS) is the first non-invasive, hand-held medical therapy applied at the neck as an adjunctive therapy to treat migraine and cluster headache through the utilization of a mild electrical stimulation to the vagus nerve that passes through the skin. Designed as a portable, easy-to-use technology, gammaCore can be self-administered by patients, as needed, without the potential side effects associated with commonly prescribed drugs. When placed on a patient’s neck over the vagus nerve, gammaCore stimulates the nerve’s afferent fibers, which may lead to a reduction of pain in patients. 

gammaCore is FDA cleared in the United States for adjunctive use for the preventive treatment of cluster headache in adult patients, the acute treatment of pain associated with episodic cluster headache in adult patients, the acute treatment of pain associated with migraine headache in adult patients, and the prevention of migraine in adult patients. gammaCore is CE-marked in the European Union for the acute and/or prophylactic treatment of primary headache (Migraine, Cluster Headache, Trigeminal Autonomic Cephalalgias and Hemicrania Continua) and Medication Overuse Headache in adults.

  • Safety and efficacy of gammaCore have not been evaluated in the following patients:
    • Patients diagnosed with narrowing of the arteries (carotid atherosclerosis)
    • Patients who have had surgery to cut the vagus nerve in the neck (cervical vagotomy)
    • Pediatric patients
    • Pregnant women
    • Patients with clinically significant hypertension, hypotension, bradycardia, or tachycardia
  • Patients should not use gammaCore if they:
    • Have an active implantable medical device, such as a pacemaker, hearing aid implant, or any implanted electronic device
    • Have a metallic device such as a stent, bone plate, or bone screw implanted at or near their neck
    • Are using another device at the same time (e.g., TENS Unit, muscle stimulator) or any portable electronic device (e.g., mobile phone)

In the US, the FDA has not cleared gammaCore for the treatment of pneumonia and/or respiratory disorders such as acute respiratory stress disorder associated with COVID-19.

Please refer to the gammaCore Instructions for Use for all of the important warnings and precautions before using or prescribing this product.

Forward-Looking Statements

This press release and other written and oral statements made by representatives of electroCore may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include, but are not limited to, statements about electroCore’s business prospects and clinical and product development plans; its pipeline or potential markets for its technologies; the timing, outcome and impact of regulatory, clinical and commercial developments; the expected date of publication of complete study results from the PREMIUM II trial and other statements that are not historical in nature, particularly those that utilize terminology such as “anticipates,” “will,” “expects,” “believes,” “intends,” other words of similar meaning, derivations of such words and the use of future dates. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, the ability to raise the additional funding needed to continue to pursue electroCore’s business and product development plans, the inherent uncertainties associated with developing new products or technologies, the ability to commercialize gammaCore™, the potential impact and effects of COVID-19 on the business of electroCore, electroCore’s results of operations and financial performance, and any measures electroCore has and may take in response to COVID-19 and any expectations electroCore may have with respect thereto, competition in the industry in which electroCore operates and overall market conditions. Any forward-looking statements are made as of the date of this press release, and electroCore assumes no obligation to update the forward-looking statements or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents electroCore files with the SEC available at www.sec.gov.

Investors:

Hans Vitzthum
LifeSci Advisors
617-430-7578
[email protected]

or

Media Contact:

Jackie Dorsky
electroCore
973-290-0097
[email protected]



Vincent Announces $2 Million Raise to Help People Discover and Diligence Alternative Investments

Indiegogo Founder Launches New Fintech Platform

New York, Dec. 08, 2020 (GLOBE NEWSWIRE) — Vincent, an online platform that helps investors gain access to alternative assets, today announced the launch of a search engine where investors can discover and diligence hundreds of alternative investment opportunities from more than 50 partnering investment platforms. 

Online investing, like much of fintech, has recently boomed as independent, savvy investors seek more ways to earn yield in response to historically low interest rates. The days of building wealth through savings accounts are over, prompting the rise of self-service investment services like Robinhood and Betterment, which allow investors more direct control over their financial futures. 

In particular, alternative investments have proven pivotal, with investors aiming to diversify their portfolios to include private assets like real estate, venture capital, or cryptocurrency, instead of focusing solely on the public markets. These assets, which have long been held by institutions and high-net-worths, are quickly becoming available to smaller investors via various online investment platforms and service providers. 

Dubbed ‘Zillow for investors,’ Vincent unifies the fragmented world of alternative investing into an easy-to-use search engine, making opportunities accessible for everyday investors. On Vincent, investors can browse, compare, and research hundreds of unique investment opportunities from partner platforms including Fundrise, Yieldstreet, StartEngine, Roofstock, Masterworks, and Otis. 

“Investment discovery for alternatives has been a pain point for investors,” says Vincent CEO Eric Cantor. “On Vincent, we’re seeing the typical investor review 25 investment offers, while 70 percent of investors search for at least two asset types.” 

Vincent, which has been in private beta since July 2020, currently indexes nearly $2 billion of available investments across asset classes including venture capital, real estate, private equity, private credit, art, collectibles, and more. To date, more than 100,000 investment searches have been conducted by 15,000 unique investors.  

Vincent is the brainchild of Indiegogo founder Slava Rubin and former Indiegogo investing lead Evan Cohen. They are joined by fintech entrepreneur Eric Cantor and technology lead Ross Cohen, former head of engineering at Mirror, which sold to Lululemon for $500 million. 

“With the alternative investment market set to grow from $9 to $14 trillion in the next five years, Vincent was the right next step on my journey to democratize access to investing,” says Rubin, Vincent co-founder and Executive Chairman. 

The trend has not gone unnoticed, as venture capitalists have poured hundreds of millions of dollars into the growing alternative investment ecosystem. The platforms on Vincent benefit from the 2012 JOBS act rules, which opened the door for general solicitation and crowdfunding online. This past month, the SEC announced expansions to those rules, which will lead to further growth and increase the availability of online alternative investment opportunities. 

Using Vincent’s search engine, investors can create custom searches tailored to fit their interests and portfolio needs. Investors can search across various platforms and filter by asset class, investment minimums, liquidity terms, and even potential return. Vincent’s backend aggregates the data, making it easy for investors to review and connect with the right investment platforms with just a few clicks. 

In conjunction with its formal launch, Vincent announced a $2 million round of capital to support its growth. Investors include Uncommon Denominator, humbition, ERA, and The Fund, as well as several strategic angels, including Jeff Fagnan (Accomplice, AngelList), Alap Shah (Sentieo), and Lazslo Bock (Google, Humu). 

About Vincent
Vincent is the most comprehensive search engine for alternative asset investing. Headquartered in New York City, we aggregate thousands of investment opportunities across real estate, venture capital, private equity, debt, art, collectibles, and more into one easy-to-navigate website. Through Vincent, investors gain unprecedented access to new, quality investment opportunities and research, entirely for free. Since July 2020, we have serviced over 100,000 investment searches by more than 15,000 unique investors. For more information, please visit www.withvincent.com and @DiscoverVincent.



Biotheranostics to premiere new data on Breast Cancer Index™ and prediction of endocrine therapy benefit at SABCS 2020

San Diego, CA, Dec. 08, 2020 (GLOBE NEWSWIRE) — New data on Biotheranostics’ Breast Cancer Index test will be highlighted at the 43rd annual San Antonio Breast Cancer Symposium (SABCS) being held virtually from December 8-12, 2020. Breast Cancer Index continues to expand on a strong body of evidence as the only commercially available genomic assay to help inform the decision of extended endocrine therapy based on prediction of benefit for HR+ early stage breast cancer patients.

Results from three independent studies will be presented during this week’s meeting, including data that will be featured in a Spotlight Session Wednesday, December 9th, as well as the General Session Friday morning, December 11th. Presentations include new results from the IDEAL study, which validated BCI as the first commercially available test with the ability to predict benefit from extended AI therapy in post-menopausal patients who have already been treated with 5 years of AI therapy. In addition, a correlative biomarker study in the Trans-aTTom cohort will also be presented. The collective evidence supports routine clinical use of BCI for HR+ early stage breast cancer as a predictive biomarker of benefit and outcome from extended endocrine therapy that is agnostic to tamoxifen and/or AI treatment.  

General Session GS4-09; Fri 12/11 10:45am CST

Correlative studies of the Breast Cancer Index (HOXB13/IL17BR) and ER, PR, AR, AR/ER ratio and Ki67 for prediction of extended endocrine benefit: a Trans-aTTom Study. Sgroi et al

Spotlight Session PD2-11; Wed. 12/9 5:15-6:30pm CST

Breast Cancer Index is a molecular signature of endocrine responsiveness that determines extended endocrine benefit independent of prognostic risk. Liefers et al

Poster Session PS17-32; Wed. 12/9 8:00am CST  

Characterization of HOXB13-induced estrogen receptor reprogramming in breast cancer cells. Treuner et al

Catherine Schnabel, Biotheranostics’ Chief Scientific Officer states, “As SABCS is the leading breast oncology meeting that presents practice-changing advancements in the field, it is an important milestone to have data from both the Trans-aTTom and IDEAL studies, which strengthen the clinical utility and distinct ability of BCI to predict which patients will benefit from extended endocrine therapy, featured this year.”

Don Hardison, Biotheranostics’ President and CEO adds, “We continue to add to the strength of our evidence with the singular goal of making Breast Cancer Index standard of care for all HR+ early stage breast cancer patients. We believe every woman should be offered a test that helps guide the joint decision related to extended endocrine therapy.”

About Breast Cancer Index

Breast Cancer Index is a molecular, gene expression-based test uniquely positioned to provide information to help physicians individualize treatment decisions for patients with early stage, HR+ breast cancer. This breakthrough test helps oncologists and patients navigate the difficult trade-off between taking steps to prevent recurrence of their disease and facing significant side effects and safety challenges related to unnecessary treatment. Breast Cancer Index holds guidelines designation from the American Joint Committee on Cancer for cancer staging based on molecular profile; ASCO, NCCN, European Group on Tumor Markers (EGTM), and St. Gallen to inform the chemotherapy decision; and ASCO and EGTM to inform the extended endocrine treatment dilemma. It is the only validated, commercially available test that provides risk of overall and late distant recurrence and predicts the likelihood of benefit from extended endocrine therapy. For more information, visit www.breastcancerindex.com.

 
About Biotheranostics

Biotheranostics, Inc. operates a CLIA-certified and CAP-accredited diagnostic laboratory in San Diego, California. Biotheranostics, Inc., is a leading healthcare provider in the oncology field assisting physicians in the treatment of cancer patients. Its suite of proprietary molecular diagnostic tests provides important information to physicians to tailor treatment to individual patients. The company’s Breast Cancer Index and CancerTYPE ID® tests address a variety of unmet medical needs in the management of cancer patients, and extensive clinical studies have confirmed the accuracy, clinical validity, clinical utility, and cost-effectiveness of the tests. Learn more at www.biotheranostics.com.



Lisa Whitmyer
Biotheranostics, Inc.
216-513-7808
[email protected]

Kronos Bio Appoints Pasit Phiasivongsa, Ph.D., as Senior Vice President, Pharmaceutical Development

SAN MATEO, Calif. and CAMBRIDGE, Mass., Dec. 08, 2020 (GLOBE NEWSWIRE) — Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Pasit Phiasivongsa, Ph.D., as senior vice president, pharmaceutical development. Dr. Phiasivongsa brings more than 20 years of experience in the biopharmaceutical industry overseeing manufacturing processes for novel medicines.

“I am delighted to welcome Pasit to the leadership team at Kronos Bio,” said Norbert Bischofberger, Ph.D., president and CEO. “Pasit has a proven track record of success in devising and executing accelerated manufacturing strategies throughout a product’s life cycle, from clinical development to commercial supply. He will be an instrumental member of our team as we prepare to begin clinical testing of KB-0742, our CKD9 inhibitor, and initiate our planned pivotal trial for entospletinib, our SYK inhibitor, next year.”

Dr. Phiasivongsa has extensive experience overseeing chemistry, manufacturing and controls (CMC) development strategies and advancing programs from proof-of-concept validation through commercial production. He most recently served as senior vice president, technical operations, at Principia Biopharma, a Sanofi company, where he led all CMC development, manufacturing and supply chain-related activities and built the company’s technical operations organization. Prior to Principia, he was vice president, pharmaceutical development, at Tobira Therapeutics (acquired by Allergan), where he was responsible for CMC, technical operations and supply chain activities, and led the intellectual property strategy and development for the company’s core assets. Earlier in his career, he held positions in drug discovery, development and manufacturing at Dynavax Technologies; Onyx Pharmaceuticals, an Amgen subsidiary; Proteolix, Inc. (acquired by Onyx Pharmaceuticals); Astex Pharmaceuticals (formerly SuperGen, Inc.); and Optimer Pharmaceuticals. He began his career as a research assistant at Cell Pathways, Inc.

“I am thrilled to be joining Kronos Bio at this transformative time when the company will soon commence clinical testing of two investigational therapies,” said Dr. Phiasivongsa. “I look forward to working with the team to advance our current programs and guide pharmaceutical development strategy for the future. Together, we have an exceptional opportunity to improve patients’ lives.”

Dr. Phiasivongsa holds a B.S. in biochemistry and a Ph.D. in pharmaceutical and chemical sciences from the University of the Pacific. He is listed on 26 U.S.-issued patents and more than 30 patent applications.

About Kronos Bio, Inc.

Kronos Bio is a clinical-stage biopharmaceutical company dedicated to discovering, developing and commercializing therapies that seek to transform the lives of those affected by cancer. The company focuses on targeting dysregulated transcription factors and the regulatory networks within cells that drive cancerous growth. Kronos Bio’s lead investigational therapy is entospletinib, a selective inhibitor targeting spleen tyrosine kinase (SYK) in development for the frontline treatment of NPM1-mutated acute myeloid leukemia (AML). The company is also developing KB-0742, an oral inhibitor of cyclin dependent kinase 9 (CDK9), for the treatment of MYC-amplified solid tumors.

Kronos Bio is based in San Mateo, Calif., and has a research facility in Cambridge, Mass. For more information, visit www.kronosbio.com or follow the company on LinkedIn.

Forward-Looking Statements

Statements in this press release that are not statements of historical fact are forward-looking statements for purposes of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. The press release, in some cases, uses terms such as “expects,” “planned,” “prepare,” “begin,” “initiate,” “commence,” “look forward,” “guide,” “intends,” “will,” “should,” “seek” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements include statements regarding Kronos Bio’s intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: Kronos Bio’s plans to begin a Phase 1/2 clinical trial of KB-0742 in patients with advanced solid tumors and the expected timing thereof; the design of such planned Phase 1/2 clinical trial, including to establish clinical proof of concept to enable potential further development; and other statements that are not historical fact. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, including, without limitation: whether Kronos Bio will be able to initiate or complete the Phase 1/2 clinical trial of KB-0742 and the planned clinical trial of ENTO on the timeline expected, if at all, including due to risks associated with the COVID-19 pandemic and risks inherent in the clinical development of novel therapeutics; risks related to Kronos Bio’s lack of experience as a company in conducting clinical trials; the risk that results of preclinical studies and early clinical trials are not necessarily predictive of future results; the risk that due to the relatively small number of patients that Kronos Bio plans to dose in the planned Phase 1/2 KB-0742 clinical trial, the results from the planned Phase 1/2 clinical trial, once completed, may be less reliable than results achieved in larger clinical trials, which may hinder Kronos Bio’s efforts to further develop and obtain regulatory approval for KB-0742; and risks associated with the sufficiency of Kronos Bio’s cash resources and need for additional capital. These and other risks are described in greater detail in Kronos Bio’s filings with the Securities and Exchange Commission (SEC), including under the heading “Risk Factors” in its Quarterly Report on Form 10-Q for the quarter ended September 30, 2020, filed with the SEC on November 18, 2020. Any forward-looking statements that are made in this press release speak only as of the date of this press release and are based on management’s assumptions and estimates as of such date. Except as required by law, Kronos Bio assumes no obligation to update the forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

Contact:

Stephanie Yao
Executive Director, Investor Relations and Corporate Communications
650-525-6605
[email protected]